Showing results (181-190 of 257) with videos related to

Sort By:
Pageof 26
Cancer Causes & Control : CCC|July 1, 1997
Serum steroids in relation to prostate cancer risk in a case-control study (Greece)L B Signorello, A Tzonou, C S Mantzoros, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 1, 1989
Prevalence of Chlamydia trachomatis infection in a population of asymptomatic women in a screening program for cervical cancerC J Meijer, J J Calame, E J de Windt, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1996
Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumoursS von Mensdorff-Pouilly, M M Gourevitch, P Kenemans, et al.
Maturitas|September 16, 2000
Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapiesH A Verheul, H J Coelingh-Bennink, P Kenemans, et al.
Fetal Diagnosis and Therapy|April 24, 2001
Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancyG G Bon, P Kenemans, A A Verstraeten, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 1, 1992
Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab')2: pharmacokinetics, tissue distribution, and tumor imagingM.R. Buist, P. Kenemans, J.B. Vermorken, et al.
Fertility and Sterility|April 15, 1999
Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal womenW M van Baal, P Kenemans, J J Emeis, et al.
British Journal of Cancer|October 2, 2008
Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levelsC Jesser, L Mucci, D Farmer, et al.
Cancer Causes & Control : CCC|January 26, 2002
Metabolic disorders and breast cancer risk (United States)J A Baron, E Weiderpass, P A Newcomb, et al.
British Journal of Obstetrics and Gynaecology|July 30, 1999
An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinomaQ Davies, A C Perkins, J C Roos, et al.
Pageof 26